PMC:7228307 / 60295-60638
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T456 | 115-123 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T455 | 0-6 | JJ | denotes | Future |
T456 | 7-17 | NNS | denotes | directions |
T457 | 18-20 | IN | denotes | in |
T458 | 21-24 | DT | denotes | the |
T459 | 25-36 | NN | denotes | development |
T460 | 37-40 | CC | denotes | and |
T461 | 41-44 | NN | denotes | use |
T462 | 45-47 | IN | denotes | of |
T463 | 48-59 | JJ | denotes | therapeutic |
T464 | 60-70 | NNS | denotes | antibodies |
T465 | 71-77 | MD | denotes | should |
T466 | 78-90 | RB | denotes | increasingly |
T467 | 91-96 | VB | denotes | mimic |
T468 | 97-103 | JJ | denotes | normal |
T469 | 104-114 | JJ | denotes | protective |
T470 | 115-123 | NN | denotes | antibody |
T471 | 124-133 | NNS | denotes | responses |
T472 | 133-134 | -COMMA- | denotes | , |
T473 | 135-140 | WDT | denotes | which |
T474 | 141-144 | VBP | denotes | are |
T475 | 145-155 | JJ | denotes | polyclonal |
T476 | 156-159 | CC | denotes | and |
T477 | 160-168 | VBN | denotes | elicited |
T478 | 169-171 | IN | denotes | in |
T479 | 172-175 | DT | denotes | the |
T480 | 176-183 | NN | denotes | context |
T481 | 184-186 | IN | denotes | of |
T482 | 187-193 | JJ | denotes | innate |
T483 | 194-202 | NN | denotes | receptor |
T484 | 203-213 | NN | denotes | engagement |
T485 | 214-219 | WDT | denotes | which |
T486 | 220-228 | VBZ | denotes | includes |
T487 | 229-232 | DT | denotes | the |
T488 | 233-236 | NNS | denotes | FcR |
T489 | 237-239 | RB | denotes | as |
T490 | 240-244 | RB | denotes | well |
T491 | 245-247 | IN | denotes | as |
T492 | 248-253 | JJ | denotes | other |
T493 | 254-264 | RB | denotes | powerfully |
T494 | 265-275 | JJ | denotes | responsive |
T495 | 276-283 | NNS | denotes | systems |
T496 | 284-293 | VBG | denotes | including |
T497 | 294-297 | DT | denotes | the |
T498 | 298-307 | JJ | denotes | Toll‐like |
T499 | 308-317 | NNS | denotes | receptors |
T500 | 318-321 | CC | denotes | and |
T501 | 322-332 | NN | denotes | complement |
T502 | 333-342 | NNS | denotes | receptors |
R467 | T456 | T455 | arg1Of | directions,Future |
R468 | T456 | T457 | arg1Of | directions,in |
R469 | T460 | T457 | arg2Of | and,in |
R470 | T460 | T458 | arg1Of | and,the |
R471 | T459 | T460 | arg1Of | development,and |
R472 | T461 | T460 | arg2Of | use,and |
R473 | T460 | T462 | arg1Of | and,of |
R474 | T464 | T462 | arg2Of | antibodies,of |
R475 | T464 | T463 | arg1Of | antibodies,therapeutic |
R476 | T456 | T465 | arg1Of | directions,should |
R477 | T467 | T465 | arg2Of | mimic,should |
R478 | T467 | T466 | arg1Of | mimic,increasingly |
R479 | T456 | T467 | arg1Of | directions,mimic |
R480 | T471 | T467 | arg2Of | responses,mimic |
R481 | T471 | T468 | arg1Of | responses,normal |
R482 | T471 | T469 | arg1Of | responses,protective |
R483 | T471 | T470 | arg1Of | responses,antibody |
R484 | T471 | T472 | arg1Of | responses,"," |
R485 | T471 | T473 | arg1Of | responses,which |
R486 | T471 | T474 | arg1Of | responses,are |
R487 | T476 | T474 | arg2Of | and,are |
R488 | T471 | T475 | arg1Of | responses,polyclonal |
R489 | T475 | T476 | arg1Of | polyclonal,and |
R490 | T477 | T476 | arg2Of | elicited,and |
R491 | T471 | T477 | arg2Of | responses,elicited |
R492 | T477 | T478 | arg1Of | elicited,in |
R493 | T480 | T478 | arg2Of | context,in |
R494 | T480 | T479 | arg1Of | context,the |
R495 | T480 | T481 | arg1Of | context,of |
R496 | T484 | T481 | arg2Of | engagement,of |
R497 | T484 | T482 | arg1Of | engagement,innate |
R498 | T484 | T483 | arg1Of | engagement,receptor |
R499 | T480 | T485 | arg1Of | context,which |
R500 | T480 | T486 | arg1Of | context,includes |
R501 | T491 | T486 | arg2Of | as,includes |
R502 | T491 | T487 | arg1Of | as,the |
R503 | T491 | T489 | arg1Of | as,as |
R504 | T491 | T490 | arg1Of | as,well |
R505 | T488 | T491 | arg1Of | FcR,as |
R506 | T495 | T491 | arg2Of | systems,as |
R507 | T495 | T492 | arg1Of | systems,other |
R508 | T495 | T493 | arg1Of | systems,powerfully |
R509 | T495 | T494 | arg1Of | systems,responsive |
R510 | T495 | T496 | arg1Of | systems,including |
R511 | T500 | T496 | arg2Of | and,including |
R512 | T500 | T497 | arg1Of | and,the |
R513 | T499 | T498 | arg1Of | receptors,Toll‐like |
R514 | T499 | T500 | arg1Of | receptors,and |
R515 | T502 | T500 | arg2Of | receptors,and |
R516 | T502 | T501 | arg1Of | receptors,complement |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T334 | 0-343 | Sentence | denotes | Future directions in the development and use of therapeutic antibodies should increasingly mimic normal protective antibody responses, which are polyclonal and elicited in the context of innate receptor engagement which includes the FcR as well as other powerfully responsive systems including the Toll‐like receptors and complement receptors. |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T455 | 115-123 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T334 | 0-343 | Sentence | denotes | Future directions in the development and use of therapeutic antibodies should increasingly mimic normal protective antibody responses, which are polyclonal and elicited in the context of innate receptor engagement which includes the FcR as well as other powerfully responsive systems including the Toll‐like receptors and complement receptors. |